obesity

News

Novo Nordisk will cut 9,000 jobs across the company as it reallocates resources toward growth and innovation in the obesity and diabetes markets.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.

News

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.

News

Telehealth startup Remedy Meds has expanded its position in the US market at a stroke with a $500m-plus deal to buy Thirty Madison.

News

Ametris launches a collaboration with pharma companies that aims to show how digital endpoints can be used in obesity trials.

News

Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy works better than Eli Lilly's fast-growing rival Zepbound.